The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Innophos Holdings's revenues will grow 3.7% and EPS will wane -18.2%.
The average estimate for revenue is $217.0 million. On the bottom line, the average EPS estimate is $0.72.
Last quarter, Innophos Holdings tallied revenue of $211.2 million. GAAP reported sales were 4.5% higher than the prior-year quarter's $202.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.79. GAAP EPS of $0.74 for Q3 were 12% lower than the prior-year quarter's $0.84 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 20.3%, 390 basis points worse than the prior-year quarter. Operating margin was 11.6%, 460 basis points worse than the prior-year quarter. Net margin was 7.9%, 140 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $870.6 million. The average EPS estimate is $3.18.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 800 members out of 823 rating the stock outperform, and 23 members rating it underperform. Among 263 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 258 give Innophos Holdings a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Innophos Holdings is outperform, with an average price target of $59.25.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Innophos Holdings. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Innophos Holdings to My Watchlist.